Chronic myeloproliferative disorder
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
AURKA contributes to Janus-kinase-2 (JAK2) activation and increased AURKA protein levels were reported in CD34+ and CD41+ cells of myeloproliferative neoplasm patients, leading to aneuploidy and aberrant megakaryopoiesis.
|
31837568 |
2020 |
Chronic myeloproliferative disorder
|
0.300 |
Biomarker
|
disease |
BEFREE |
While JAK2 inhibitor therapy provides substantial clinical benefit in MPN patients, the identification of alternative therapeutic targets is needed to reverse MPN pathogenesis and control malignant hematopoiesis.
|
31750881 |
2020 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Later studies identified that PMF, as the others MPNs, is associated with mutations activating the thrombopoietin/JAK2 axis raising great hope that JAK inhibitors may be effective to treat the disease.
|
31749302 |
2020 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) share similar molecular characteristics in that they frequently harbor hotspot mutations in JAK2, CALR or MPL, leading to activated JAK/STAT signaling.
|
31071164 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Calreticulin (CALR) gene mutations are currently recommended as biomarkers in diagnosis of patients with myeloproliferative neoplasms (MPN) with Jak2 V617F negative phenotype.
|
31248375 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Myeloproliferative neoplasms (MPNs) are associated with somatic mutations of genes including JAK2, CALR, or MPL in hematopoietic stem cells.
|
31377025 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In the absence of BCR-ABL, the conventional diagnostic algorithm recommends JAK2 V617F mutation testing to support diagnosis of other MPN diseases such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
|
30772299 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
Biomarker
|
disease |
BEFREE |
We enrolled 73 patients with JAK2-positive MPN from our Hematology Clinic in the period August 2015 to Feb 2017.
|
31229378 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
Biomarker
|
disease |
BEFREE |
This demonstrates that compensatory ERK activation limits the efficacy of JAK2 inhibition and dual JAK/MEK inhibition provides an opportunity for improved therapeutic efficacy in MPNs and in other malignancies driven by aberrant JAK-STAT signaling.
|
30730307 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Myeloproliferative neoplasms (MPNs) driver mutations are usually found in JAK2, MPL, and CALR genes; however, 10%-15% of cases are triple negative (TN).
|
30295334 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
|
31255914 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The V617F mutation in the JH2 domain of JAK2 is an oncogenic driver in several myeloproliferative neoplasms (MPNs), including essential thrombocythemia, myelofibrosis, and polycythemia vera (PV).
|
31697804 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
Biomarker
|
disease |
BEFREE |
This review focusses on the role of JAK2 and the JAK/STAT pathway in MPN and LPN, whether there is a role for the genetic background in the occurrence of both MPN and LPN, and whether there is a role for cytoreductive drugs in the occurrence of both MPN and LPN.
|
31833567 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The major weakness of most knock-in JAK2V617F mouse models is the presence of the JAK2 mutation in all rather than in a few hematopoietic stem cells (HSC), like in human "early stage" myeloproliferative neoplasms (MPN).
|
31697834 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Consistent with this, treatment with a small molecule IRAK1/4 inhibitor rescued the aberrantly elevated IL-1β production in the JAK2-V617F MPN model.
|
31434702 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The link between MA and JAK2 mutant allele burden implies that allele burden has a role not only in clinical phenotype and disease evolution in MPN patients, but also in the overall methylation landscape of the mutated cells.
|
31563618 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.
|
30463063 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
JAK2 mutations in myeloproliferative neoplasms (MPNs) are associated with the germline GGCC (46/1) haplotype.
|
30516848 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Primary Myelofibrosis (PMF) is a myeloproliferative disorder associated with JAK2V617F, Calreticulin (CALR) indels, and MPLW515L/K mutations activating the tyrosine kinase JAK2 and its downstream signaling pathway.
|
31369569 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
While TERT rs2736100_C tended to have a more general, non-specific effect on all MPNs, the JAK2 46/1 haplotype was essentially predisposed to the JAK2 V617F-positive MPNs.
|
31571131 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The identification of JAK2 mutations as disease-initiating in myeloproliferative neoplasms (MPNs) has led to new and effective therapies for these diseases.
|
30829649 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In this study, we identified the first CALR gene mutational landscape in Moroccan patients with MPN nonmutated for the JAK2 gene.
|
28340692 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
Biomarker
|
disease |
BEFREE |
This study aims to explore the selective JAK2<sup>V617F</sup> inhibitor, evaluate the efficacy and possible mechanism of ZT55 on MPN.
|
30717771 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The occurrence in most patients affected by myeloproliferative neoplasms (MPNs) of driver mutations resulting in the constitutive activation of JAK2-dependent signaling identified the deregulated JAK-STAT signal transduction pathway as the major pathogenic mechanism of MPNs.
|
31788449 |
2019 |
Chronic myeloproliferative disorder
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The objective of this review is to characterize studies on BCR-ABL1-negative chronic myeloproliferative neoplasms and to compare the frequency of JAK2, MPL and CALR mutations in PV, ET and PMF.
|
31208359 |
2019 |